Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial
Open Access
- 31 July 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 97 (5), 598-604
- https://doi.org/10.1038/sj.bjc.6603903
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2009
- Impact of Interferon-α in Combined Chemoradioimmunotherapy for Pancreatic Adenocarcinoma (CapRI): First Data From the ImmunomonitoringJournal of Immunotherapy, 2007
- Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse modelGut, 2004
- Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cellsImmunobiology, 2003
- Intratracheal Macrophage-Activating Lipopeptide-2 Reduces Metastasis in the Rat LungAmerican Journal of Respiratory Cell and Molecular Biology, 2003
- Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological TherapyJournal of Immunotherapy, 2002
- Chirurgische Palliation beim Pankreascarcinom Ergebnisse aus einem 7-JahresintervallDer Chirurg, 2001
- MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?Innate Immunity, 2000
- In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362Cancer Immunology, Immunotherapy, 1991